RAPGEF5 Antibody

What is RAPGEF5 and what are its primary biological functions?

RAPGEF5 (also known as GFR, MR-GEF, or Repac) functions as a guanine nucleotide exchange factor for RAP1A, RAP2A, and MRAS/M-Ras-GTP. Its primary biological role involves the regulation of nuclear translocation of β-catenin, independent of cytoplasmic stabilization and the importin α/β1 mediated transport system. RAPGEF5 is critical in Wnt signaling pathways, particularly in left-right patterning during embryonic development. Research has demonstrated that RAPGEF5 activates nuclear Raps to facilitate the nuclear transport of β-catenin, thereby identifying new potential targets for modulating Wnt signaling in disease states . Additionally, it has been implicated in congenital heart disease and heterotaxy, highlighting its importance in developmental processes .

What types of RAPGEF5 antibodies are currently available for research applications?

Current research tools include both monoclonal and polyclonal antibodies against RAPGEF5. Rabbit recombinant monoclonal antibodies (such as clone EPR6882) are available in carrier-free formats designed for conjugation with fluorochromes, metal isotopes, oligonucleotides, and enzymes . These are suitable for multiple applications and demonstrate reactivity across human, mouse, and rat samples. Polyclonal antibodies derived from rabbit are also available, which are affinity-purified using epitope-specific immunogens . These antibodies are designed to detect endogenous levels of total RAPGEF5 protein across human and mouse samples .

Which experimental applications are RAPGEF5 antibodies validated for?

RAPGEF5 antibodies have been validated for multiple research applications. The rabbit recombinant monoclonal antibodies are suitable for immunohistochemistry on paraffin-embedded sections (IHC-P), Western blot (WB), immunocytochemistry/immunofluorescence (ICC/IF), and intracellular flow cytometry . They have been tested and validated on human, mouse, and rat samples across these various applications . Polyclonal antibodies may have more limited validated applications, with some specifically validated only for Western blot analysis in human and mouse samples . Researchers should carefully review the validation data provided by manufacturers before selecting an antibody for their specific application.

How does RAPGEF5 regulate Wnt signaling and β-catenin nuclear translocation?

RAPGEF5 regulates Wnt signaling through a novel mechanism independent of the canonical β-catenin cytoplasmic destruction machinery. Research indicates that RAPGEF5 acts downstream in the Wnt signaling pathway by facilitating the nuclear translocation of β-catenin . Knockdown studies have demonstrated that RAPGEF5 depletion affects the active (unphosphorylated) pool of β-catenin that translocates into the nucleus much more severely than total β-catenin levels .

Mechanistically, RAPGEF5 is proposed to activate nuclear Raps that facilitate β-catenin nuclear transport. This function operates independently of the GSK3-mediated β-catenin degradation pathway, as demonstrated by experiments where RAPGEF5 knockdown counteracted the effects of GSK3 inhibition by BIO (a chemical inhibitor) . These findings suggest RAPGEF5 provides a novel regulatory layer for Wnt signaling beyond the well-established cytoplasmic destruction complex, focusing instead on nuclear transport mechanisms.

What methodological approaches can be used to study RAPGEF5's role in nuclear translocation?

To investigate RAPGEF5's role in nuclear translocation, researchers can employ several methodological approaches:

• Subcellular fractionation and Western blot: Separate nuclear and cytoplasmic fractions of cells with and without RAPGEF5 knockdown/overexpression, followed by Western blot analysis to quantify β-catenin distribution between compartments .

• TOPFlash luciferase assays: These place luciferase expression under the control of TCF/LEF binding sites to measure Wnt pathway activation through nuclear β-catenin activity. By manipulating RAPGEF5 levels and measuring luciferase signal changes, researchers can assess its impact on nuclear β-catenin function .

• Immunofluorescence co-localization studies: Using RAPGEF5 antibodies in combination with β-catenin antibodies to visualize their spatial distribution within cells through confocal microscopy .

• Proximity ligation assays: To detect and visualize potential direct interactions between RAPGEF5 and β-catenin or other nuclear transport components.

• Rescue experiments: Combining RAPGEF5 knockdown with expression of constitutively active downstream components to pinpoint where in the pathway RAPGEF5 functions .

How can RAPGEF5 antibodies be used to investigate its role in disease models?

RAPGEF5 antibodies can be instrumental in investigating disease models through several approaches:

• Expression profiling in disease tissues: Immunohistochemistry using RAPGEF5 antibodies on disease tissues (such as congenital heart defects, intrahepatic cholangiocarcinoma) to assess correlation between RAPGEF5 expression and disease severity .

• Functional studies in developmental models: Utilizing immunodetection of RAPGEF5 in developmental models (like Xenopus embryos) after morpholino knockdown or CRISPR targeting to understand its role in left-right patterning defects .

• Signaling pathway analysis: Western blot analysis of RAPGEF5 and downstream effectors (β-catenin, Rap1) in disease models to map dysregulated signaling networks .

• Co-immunoprecipitation studies: Using RAPGEF5 antibodies to pull down interacting proteins in disease models to identify altered protein interactions contributing to pathology.

• In vivo imaging: Conjugating RAPGEF5 antibodies with imaging agents for visualizing expression patterns in animal disease models.

For intrahepatic cholangiocarcinoma specifically, RAPGEF5-related circular RNA (circ-RAPGEF5) has been implicated in tumor progression through the regulation of SUMOylation . Antibodies against RAPGEF5 could help elucidate connections between the host gene and its circular RNA derivatives in this disease context.

What are the optimal conditions for using RAPGEF5 antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with RAPGEF5 antibodies, researchers should consider the following protocol elements:

• Fixation and embedding: Formalin/PFA-fixed paraffin-embedded sections have been validated for RAPGEF5 detection .

• Antigen retrieval: Heat-mediated antigen retrieval using epitope retrieval solution at pH 6.0 (such as Bond™ Epitope Retrieval Solution 1) is recommended based on validated protocols .

• Antibody dilution: For the rabbit monoclonal antibody [EPR6882], a 1/100 dilution (approximately 1.19 μg/mL) has been validated for IHC applications .

• Detection system: Rabbit-specific IHC polymer detection kits with HRP/DAB have shown good results for visualizing RAPGEF5 in tissue sections .

• Controls: Include negative controls using PBS instead of primary antibody, and positive controls using tissues known to express RAPGEF5 (human testis, mouse liver, and rat cerebrum have been validated) .

• Counterstaining: Hematoxylin counterstaining provides good nuclear contrast for evaluating RAPGEF5 expression patterns .

Automated immunostaining platforms (such as Leica Biosystems BOND® RX instrument) can provide consistent results for RAPGEF5 detection across multiple samples .

What is the recommended protocol for Western blot detection of RAPGEF5?

For optimal Western blot detection of RAPGEF5, follow these methodological guidelines:

• Sample preparation: Prepare tissue or cell lysates in appropriate lysis buffer containing protease inhibitors. RAPGEF5 has been successfully detected in various lysates including human brain tissue and rat brain lysates .

• Protein loading: Load approximately 20 μg of total protein per lane for tissue lysates .

• Gel percentage: Use an appropriate percentage gel that provides good resolution in the 60-70 kDa range, where RAPGEF5 is expected to be detected (observed band size: 68 kDa) .

• Transfer conditions: Standard transfer conditions for proteins of this size range are appropriate (wet transfer recommended for larger proteins).

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST.

• Primary antibody incubation: For monoclonal antibodies, dilutions around 1/1000 are typically effective, but researchers should follow manufacturer-specific recommendations .

• Secondary antibody: Anti-rabbit IgG conjugated to HRP with minimal cross-reactivity to human IgG at 1/2000 dilution has been validated .

• Detection: Standard ECL detection systems are appropriate for visualizing the RAPGEF5 signal.

• Expected result: A band at approximately 68 kDa representing RAPGEF5 . Some antibodies may detect a band at 60 kDa depending on the specific antibody and sample preparation .

How can immunofluorescence be optimized for RAPGEF5 detection in cell cultures?

For optimal immunofluorescence detection of RAPGEF5 in cultured cells, consider the following protocol recommendations:

• Cell fixation: Fix cells with 4% paraformaldehyde to preserve cellular architecture and protein localization .

• Permeabilization: Permeabilize fixed cells with 0.1% Triton X-100 to allow antibody access to intracellular targets .

• Blocking: Block with appropriate serum (typically 5-10% normal serum from the same species as the secondary antibody) to reduce non-specific binding.

• Primary antibody dilution: For the rabbit monoclonal antibody [EPR6882], a 1/500 dilution (approximately 0.24 μg/ml) has been validated for ICC/IF applications .

• Co-staining options: RAPGEF5 can be co-stained with cytoskeletal markers (such as alpha-tubulin) to provide cellular context. A validated approach used Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] at 1/200 dilution (2.5 μg/ml) .

• Secondary antibody: Goat anti-rabbit IgG conjugated to Alexa Fluor® 488 at 1/1000 dilution (2 μg/ml) has been validated .

• Nuclear counterstain: DAPI is recommended for nuclear visualization, which helps assess the nuclear/cytoplasmic distribution of RAPGEF5 .

• Controls: Include a secondary antibody-only control (PBS instead of primary antibody) to assess background fluorescence .

• Imaging: Confocal microscopy is preferred for detailed subcellular localization studies of RAPGEF5.

This protocol has been validated in HeLa cells and may require optimization for other cell types .

What are common pitfalls when using RAPGEF5 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with RAPGEF5 antibodies:

• Multiple bands in Western blot:

  • Problem: Additional bands beyond the expected 68 kDa may appear.

  • Solution: Validate antibody specificity using positive and negative controls. Consider using different antibody clones that target different epitopes. Optimize protein extraction and denaturation conditions to reduce proteolytic degradation.

• Weak or absent signal:

  • Problem: Low or no detection of RAPGEF5 despite expected expression.

  • Solution: Increase antibody concentration, extend incubation time, optimize antigen retrieval (for IHC), or try more sensitive detection systems. Ensure the sample preparation preserves the epitope recognized by the antibody.

• High background:

  • Problem: Non-specific staining making it difficult to interpret specific RAPGEF5 signal.

  • Solution: Increase blocking time/concentration, optimize antibody dilution, increase washing steps duration/frequency, and use more specific secondary antibodies with minimal cross-reactivity .

• Inconsistent results across experiments:

  • Problem: Variable RAPGEF5 detection between experimental replicates.

  • Solution: Standardize protocols, use consistent sample preparation methods, and include internal controls in each experiment. Consider batch testing antibodies and preparing aliquots to avoid freeze-thaw cycles.

• Discrepancy between different detection methods:

  • Problem: Different results when using the same antibody across various applications (WB vs. IHC vs. ICC).

  • Solution: Recognize that epitope accessibility varies between applications and may require technique-specific optimization. Validate findings using complementary approaches or different antibody clones.

How can researchers validate the specificity of RAPGEF5 antibodies?

To ensure reliable research outcomes, validating RAPGEF5 antibody specificity is crucial:

• Genetic manipulation approaches:

  • Perform antibody staining in RAPGEF5 knockdown/knockout models to confirm signal reduction.

  • Compare with rescue experiments where RAPGEF5 expression is restored (e.g., using human RAPGEF5 mRNA in morphant models) .

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide before application to samples.

  • Signal should be significantly reduced if the antibody is specific.

• Multiple antibody validation:

  • Use different antibodies targeting distinct RAPGEF5 epitopes to confirm consistent detection patterns.

  • Compare monoclonal and polyclonal antibodies for concordant results.

• Recombinant protein controls:

  • Include purified or overexpressed RAPGEF5 protein as a positive control in Western blots.

  • This helps confirm the expected molecular weight and antibody reactivity.

• Cross-species reactivity testing:

  • Verify antibody performance across different species based on epitope conservation.

  • Confirm results align with expected homology patterns (many RAPGEF5 antibodies react with human, mouse, and rat samples) .

• Application-specific controls:

  • For IHC/ICC: Include tissue/cells known to express or lack RAPGEF5.

  • For flow cytometry: Include fluorescence-minus-one (FMO) controls.

  • For WB: Include molecular weight markers and both positive and negative tissue controls .

How can researchers accurately quantify RAPGEF5 expression levels?

Accurate quantification of RAPGEF5 expression requires methodological rigor:

• Western blot quantification:

  • Use loading controls (β-actin, GAPDH) to normalize RAPGEF5 signals.

  • Apply densitometry software (ImageJ, ImageLab) for band intensity quantification.

  • Generate standard curves using recombinant RAPGEF5 protein for absolute quantification.

  • Use technical and biological replicates (minimum n=3) for statistical validation.

• Immunohistochemistry quantification:

  • Employ digital pathology software for unbiased quantification of staining intensity.

  • Use H-score or Allred scoring systems that combine staining intensity and percentage of positive cells.

  • Include calibration standards with known RAPGEF5 expression levels.

  • Have multiple independent observers score samples blindly to reduce bias.

• Flow cytometry quantification:

  • Use mean fluorescence intensity (MFI) for relative RAPGEF5 expression quantification.

  • Include fluorescent calibration beads to convert arbitrary units to molecules of equivalent soluble fluorochrome (MESF).

  • Perform appropriate compensation when using multiple fluorophores.

  • Implement consistent gating strategies across experiments.

• RT-qPCR correlation:

  • Correlate protein expression data with mRNA levels for validation.

  • Design specific primers spanning exon-exon junctions to avoid genomic DNA amplification.

  • Normalize to validated reference genes stable in your experimental system.

• Subcellular fractionation:

  • Separate nuclear and cytoplasmic fractions to quantify RAPGEF5 distribution.

  • Use fraction-specific markers (lamin for nucleus, GAPDH for cytoplasm) to validate separation quality.

  • This approach is particularly relevant given RAPGEF5's role in nuclear translocation of β-catenin .

How can RAPGEF5 antibodies be utilized to study its role in Wnt signaling and developmental disorders?

RAPGEF5 antibodies provide versatile tools for investigating Wnt signaling and developmental disorders:

• Developmental time-course studies:

  • Use RAPGEF5 antibodies to track expression patterns throughout embryonic development in model organisms.

  • Correlate expression with critical developmental events, particularly in left-right patterning and heart development .

• Co-localization with Wnt pathway components:

  • Perform dual immunofluorescence studies to visualize RAPGEF5 alongside β-catenin and other Wnt pathway components.

  • Analyze co-localization patterns in normal versus pathological developmental contexts .

• Patient tissue analysis:

  • Apply RAPGEF5 immunohistochemistry to tissue samples from patients with congenital heart disease or heterotaxy.

  • Compare expression patterns with matched controls to identify disease-associated alterations .

• Mechanistic intervention studies:

  • Use RAPGEF5 antibodies to monitor protein expression following experimental interventions targeting the Wnt pathway.

  • Assess changes in subcellular localization of RAPGEF5 and β-catenin after GSK3 inhibition or other Wnt pathway modifications .

• Morpholino/CRISPR validation:

  • Confirm efficacy of RAPGEF5 knockdown or knockout in developmental models using antibody-based detection methods.

  • Correlate protein reduction with observed phenotypes to establish causality .

• Structure-function analysis:

  • Use epitope-specific antibodies to identify functional domains of RAPGEF5 involved in β-catenin nuclear translocation.

  • Map interactions between RAPGEF5 and nuclear transport machinery components.

What are the implications of circ-RAPGEF5 in cancer research and how can antibodies contribute to this field?

Recent research has identified a circular RNA derived from the RAPGEF5 gene (circ-RAPGEF5) with significant implications for cancer research:

• Expression correlation studies:

  • Use RAPGEF5 antibodies alongside circ-RAPGEF5 detection methods to analyze correlations between the host gene protein and its circular RNA derivative.

  • Examine these correlations in cancerous versus non-cancerous tissues, particularly in intrahepatic cholangiocarcinoma (ICC) .

• Mechanistic investigation of SUMOylation:

  • Apply RAPGEF5 antibodies in co-immunoprecipitation studies to identify interactions with SUMOylation machinery components.

  • Investigate how circ-RAPGEF5 affects RAPGEF5 protein expression and its downstream impact on SAE1 stabilization and SUMOylation .

• Prognostic biomarker validation:

  • Use RAPGEF5 immunohistochemistry in patient cohorts to assess its value as a prognostic biomarker.

  • Compare with circ-RAPGEF5 expression to determine if the protein, circular RNA, or both best predict patient outcomes in ICC .

• Therapeutic targeting assessment:

  • Monitor RAPGEF5 protein expression changes in response to interventions targeting circ-RAPGEF5.

  • Evaluate downstream effects on SUMOylation and AKT activation as potential therapeutic mechanisms .

• miRNA-mediated regulation:

  • Investigate how miR-3185, which interacts with both circ-RAPGEF5 and SAE1, affects RAPGEF5 protein expression.

  • Use antibodies to assess protein level changes in response to miRNA modulation .

• Multi-omics integration:

  • Combine RAPGEF5 protein expression data with transcriptomic and genomic analyses to build comprehensive tumor progression models.

  • Identify convergent pathways between RAPGEF5 protein function and circ-RAPGEF5 regulatory networks .